210 MAIN STREET WEST, BAUDETTE, MN
Stockholders Approve Amended 2022 Stock Incentive Plan
Investor Presentation
Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
Annual Report to Security Holders
ANI Pharmaceuticals Dismisses EisnerAmper as Independent Accountant
Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Confidential Treatment Order
Submission Upload